Rumi Scientific
Rumi Scientific is a research-driven biotechnology company focused on accelerating early-stage drug discovery for neurodevelopmental and genetic diseases using a proprietary high-throughput organoid-like platform that mimics human brain development. Their technology, based on human embryonic stem cells and advanced machine learning, enables identification of novel therapeutic targets and compounds by modeling disease-specific mutations in brain tissue organoids called neuroloids. The platform allows rapid phenotypic screening to predict drug efficacy, particularly targeting rare and challenging CNS and renal indications with high unmet medical needs. Collaborations with institutions like Mount Sinai's Seaver Autism Center highlight their translational approach to discovering treatments for rare genetic disorders tied to autism and Huntington's Disease. Headquartered in New York City, Rumi Scientific leverages cutting-edge stem cell biology, gene editing, and AI to de-risk drug development and improve therapeutic success in neurological diseases.
Rumi Scientific
Rumi Scientific is a research-driven biotechnology company focused on accelerating early-stage drug discovery for neurodevelopmental and genetic diseases using a proprietary high-throughput organoid-like platform that mimics human brain development. Their technology, based on human embryonic stem cells and advanced machine learning, enables identification of novel therapeutic targets and compounds by modeling disease-specific mutations in brain tissue organoids called neuroloids. The platform allows rapid phenotypic screening to predict drug efficacy, particularly targeting rare and challenging CNS and renal indications with high unmet medical needs. Collaborations with institutions like Mount Sinai's Seaver Autism Center highlight their translational approach to discovering treatments for rare genetic disorders tied to autism and Huntington's Disease. Headquartered in New York City, Rumi Scientific leverages cutting-edge stem cell biology, gene editing, and AI to de-risk drug development and improve therapeutic success in neurological diseases.